Cabometyx
Generic name: Cabozantinib
Usage of Cabometyx
Cabometyx is a kinase inhibitor, a type of enzyme inhibitor that blocks the action of certain protein kinases.
Cabometyx is used to treat advanced kidney cancer, sometimes in combination with another medicine called nivolumab.
Cabometyx is used to treat liver cancer (hepatocellular carcinoma) in people who have been previously treated with sorafenib.
Cabometyx is also used to treat a type of thyroid cancer called differentiated thyroid cancer (DTC) that has spread, and has progressed after treatment with a VEGFR-targeted treatment, and can no longer be treated with, or you are not able to receive radioactive iodine.
Cabometyx side effects
Get emergency medical help if you have signs of an allergic Reaction to Cabometyx: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Cabometyx may cause a perforation (a hole or tear) or a fistula (an abnormal pasSageway) within your stomach or intestines. Call your doctor if you have severe stomach pain, or if you feel like you are choking and gagging when you eat or drink.
Call your doctor at once if you have:
Your future doses of Cabozantinib may be delayed or permanently discontinued if you have certain side effects.
Common Cabometyx side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Cabometyx
To make sure Cabometyx is safe for you, tell your doctor if you have:
You may need to have a negative pregnancy test before starting this treatment.
Cabozantinib may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using Cabometyx and for at least 4 months after your last dose. Tell your doctor if you think you might be pregnant.
Cabozantinib may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because Cabometyx can harm an unborn baby.
You should not breastfeed while using Cabometyx, and for at least 4 months after your last dose.
How to use Cabometyx
Usual Adult Dose for Renal Cell Carcinoma:
Tablets: -As a single agent: 60 mg orally once a day until patient no longer experiences clinical benefit or uNACceptable toxicity occurs -In combination with nivolumab: 40 mg once a day until disease progression or unacceptable toxicity Comment: When administering this drug in combination with nivolumab, refer to the nivolumab prescribing information. Uses: -For patients with advanced renal cell carcinoma (RCC) -In combination with nivolumab, indicated for the first-line treatment of patients with advanced RCC
Usual Adult Dose for Hepatocellular Carcinoma:
Tablets: 60 mg orally once a day until patient no longer experiences clinical benefit or unacceptable toxicity occurs Use: For patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Usual Adult Dose and Pediatric Dose for Differentiated Thyroid Cancer
-As as a single agent for adult and pediatric patients 12 years of age and older with BSA greater than or equal to 1.2 m2 is 60 mg once daily until disease progression or unacceptable toxicity
-As as a single agent in pediatric patients 12 years of age and older with BSA less than 1.2 m2 is 40 mg once daily until disease progression or unacceptable toxicity.
Use: locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
Warnings
Cabometyx may cause a perforation (a hole or tear) or a fistula (an abnormal passageway) within your stomach or intestines. This medicine can also increase your risk of serious bleeding.
Call your doctor if you have: severe stomach pain, choking or gagging when you eat or drink, unusual bleeding, bloody or tarry stools, heavy menstrual bleeding, or if you cough up blood.
What other drugs will affect Cabometyx
Sometimes it is not safe to use certain medications at the SAMe time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Other drugs may interact with cabozantinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Popular FAQ
Cabometyx (cabozantinib) is a chemotherapy drug that is used to treat patients with advanced renal cell carcinoma (kidney cancer), including as a first-line treatment when used in combination with Opdivo (nivolumab), and patients with hepatocellular carcinoma (liver cancer) who have previously been treated with Nexavar (sorafenib). It is also used to treat differentiated thyroid cancer that has spread and progressed after VEGFR-targeted treatment in people who can no longer be treated with radioactive iodine or who are unable to receive that treatment. It is taken once daily. Cabometyx comes in tablet form and is available in three different strength yellow tablets including a: 60 mg oval tablet 40 mg triangular tablet 20 mg round tablet Continue reading
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor, which works by helping to stop the out-of-control growth that cancer cells display. Carbometyx works by blocking the signals between cells that promote the growth of new blood vessels and encourage cells to divide and grow. In doing so, it decreases the ability of tumors to spread (metastasize) to other parts of the body and invade surrounding areas. Continue reading
Cabometyx (cabozantinib) is taken until disease progression - the cancer starts to get worse - or you can no longer tolerate therapy because of the side effects or adverse reactions. In clinical trials the median amount of time patients took Cabometyx for before their cancer progressed was: METEOR trial - 7.4 months (95% CI 5.6, 9.1) CABOSUN trial - 8.6 months (95% CI 6.8, 14.0) CELESTIAL trial - 5.2 months (95% CI 4.0, 5.5) CHECKMATE-9ER trial - 16.6 months (95% CI 12.5, 24.9) COSMIC-311 - 11 months (95% CI 7.4, 13.8) Continue reading
How successful Cabometyx (cabozantinib) is can be measured by how: Long patients take the treatment for Long patients survive for without their cancer getting worse (progression-free survival) Many months patients remain alive for while taking the treatment Many patients respond to the drug Continue reading
Cabometyx (cabozantinib) does not cure advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) or advanced or metastatic differentiated thyroid cancer. Instead it helps to slow the progression of cancer, potentially enabling patients to live longer. Continue reading
Cabometyx and Cometriq are two brand name drugs that both contain the same active ingredient cabozantinib, but they are not interchangeable. Cabometyx comes in the form of a tablet (20, 40 and 60 mg) and is used to treat advanced renal cell carcinoma (RCC), advanced RCC as a first-line treatment in combination with nivolumab, hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib, and ocally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy in people who do not respond to or are unable to take radioactive iodine. Cometriq comes in the form of a capsule (20 and 80 mg) and is used to treat progressive metastatic medullary thyroid cancer. Continue reading
Cabometyx (cabozantinib) is a chemotherapy drug that is used to treat patients with advanced renal cell carcinoma (kidney cancer), including as a first-line treatment when used in combination with Opdivo (nivolumab), and patients with hepatocellular carcinoma (liver cancer) who have previously been treated with Nexavar (sorafenib). It is also used to treat differentiated thyroid cancer that has spread and progressed after VEGFR-targeted treatment in people who can no longer be treated with radioactive iodine or who are unable to receive that treatment. It is taken once daily. Cabometyx comes in tablet form and is available in three different strength yellow tablets including a: 60 mg oval tablet 40 mg triangular tablet 20 mg round tablet Continue reading
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor, which works by helping to stop the out-of-control growth that cancer cells display. Carbometyx works by blocking the signals between cells that promote the growth of new blood vessels and encourage cells to divide and grow. In doing so, it decreases the ability of tumors to spread (metastasize) to other parts of the body and invade surrounding areas. Continue reading
Cabometyx (cabozantinib) is taken until disease progression - the cancer starts to get worse - or you can no longer tolerate therapy because of the side effects or adverse reactions. In clinical trials the median amount of time patients took Cabometyx for before their cancer progressed was: METEOR trial - 7.4 months (95% CI 5.6, 9.1) CABOSUN trial - 8.6 months (95% CI 6.8, 14.0) CELESTIAL trial - 5.2 months (95% CI 4.0, 5.5) CHECKMATE-9ER trial - 16.6 months (95% CI 12.5, 24.9) COSMIC-311 - 11 months (95% CI 7.4, 13.8) Continue reading
How successful Cabometyx (cabozantinib) is can be measured by how: Long patients take the treatment for Long patients survive for without their cancer getting worse (progression-free survival) Many months patients remain alive for while taking the treatment Many patients respond to the drug Continue reading
Cabometyx (cabozantinib) does not cure advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) or advanced or metastatic differentiated thyroid cancer. Instead it helps to slow the progression of cancer, potentially enabling patients to live longer. Continue reading
Cabometyx and Cometriq are two brand name drugs that both contain the same active ingredient cabozantinib, but they are not interchangeable. Cabometyx comes in the form of a tablet (20, 40 and 60 mg) and is used to treat advanced renal cell carcinoma (RCC), advanced RCC as a first-line treatment in combination with nivolumab, hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib, and ocally advanced or metastatic differentiated thyroid cancer that has progressed following VEGFR-targeted therapy in people who do not respond to or are unable to take radioactive iodine. Cometriq comes in the form of a capsule (20 and 80 mg) and is used to treat progressive metastatic medullary thyroid cancer. Continue reading
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions